Clinical Trials Browser

Phase 2/3 × OTHER × daratumumab × Clear all

NCT04513639 2025-03-20

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Phase 2/3 Recruiting

Multiple Myeloma

NCT02419118 2017-11-07

DARA

Phase 2/3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell